



Reference list

CliniMACS[®] Cytokine Capture System (IFN-gamma)

Clinical Data

Virus-specific T cells

CMV

Early Experience With CliniMACS Prodigy CCS (IFN-gamma) System in Selection of Virus-specific T Cells From Third-party Donors for Pediatric Patients With Severe Viral Infections After Hematopoietic Stem Cell Transplantation

Kállay, K., Kassa, G., Réti, M., Karászi, E., Sinkó, J., Goda, V., Stréhn, A., Csordás, K., Horváth, O., Szederjesi, A., Tasnády, S., Hardi, A., and Kriván, G. (2017) *J Immunother., ePub*

Effective treatment of refractory CMV reactivation after allogeneic stem cell transplantation with In Vitro-generated CMV pp65-specific CD8+ T-cell lines.

Meiji, P., Jedema, I., Zandvliet, M. L., van der Heiden, P. L. J., van de Meent, M., van Egmond, H. M. E., van Liempt, E., Hoogstraten, C., Kruithof, S., Veld, S., Marijt, W. A., von dem Borne, P. A., Lankester, A. C., Halkes, C. J. M, and Falkenburg, J. H. F. (2012) *J. Immunther., 35:621-628*

Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation.

Peggs, K. S., Thomson, K., Samuel, E., Dyer, G., Armoogum, J., Chakraverty, R., Pang, K., Mackinnon, S., and Lowdell, M. W. (2011) *Clin. Infect. Dis., 52:49-57.*

Adoptive transfer of pp-65 specific T-cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation.

Feuchtinger, T., Opherk, K., Bethge, W.A., Topp, M.S., Schuster, F.R., Weissinger, E.M., Mohty, M., Or, R., Maschan, M., Schumm, M., Hamprecht, K., Handgretinger, R., Lang, P., and Einsele, H. (2010) *Blood,116:4360-7.*

Adoptive T-cell therapy of a lung transplanted patient with severe CMV disease and resistance to antiviral therapy.

Brestrich, G., Zwinger, S., Fischer, A., Schmück, M., Röhmhild, A., Hammer, M. H., Kurtz, A., Uharek, L., Knosalla, C., Lehmkuhl, H., Volk, H. D., and Reinke, P.(2009) *J. Immunother.,32:932-40*

Adoptive cellular therapy for cytomegalovirus infection following allogeneic stem cell transplantation using virus-specific T cells

Mackinnon, S., Thomson, K., Verfuether, S., Peggs, K., Lowdell M. (2008) *Blood Cells, Molecules, and Diseases 40: 63–67*

Five donors-one recipient: modeling a mosaic of granulocytes, natural killer and T cells from cord blood and third-party donors.

Schöttker, B., Feuchtinger, T., Schumm, M., Klinker, E., Handgretinger, R., Einsele, H., and Stuhler, G. (2008) *Nat. Clin. Pract. Oncol., 5:29*

EBV

Adoptive transfer of Epstein-Barr Virus (EBV) nuclear antigen 1-specific T cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem cell transplantation.

Icheva, V., Kayser, S., Wolff, D., Tuve, S., Kyzirakos, C., Bethge, W., Greil, J., Albert, H., Schwinger, W., Nathrath, M., Schumm, M., Stevanovic, S., Handgretinger, R., and Lang, P., Feuchtinger, T. (2012) J. Clin. Oncol., 31:39-48

Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells.

Moosmann, A., Bigalke, I., Tischer, J., Schirrmann, L., Kasten, J., Tippmer, S., Leeping, M., Prevalsek, D., Jaeger, G., Ledderose, G., Mautner, J., Hammerschmidt, W., Schendel, D. J., and Kolb, H. J. (2010) Blood, 115:2960-70.

AdV

Curative or pre-emptive adenovirus-specific T cell transfer from matched unrelated or third party haploidentical donors after HSCT, including UCB transplantations: a successful phase I/II multicenter clinical trial.

Qian, C., Campidelli, A., Wang, Y., Cai H., Venard V., Jeulin H., Dalle, J.H., Pochon C., D'aveni, M., Bruno B., Paillard C., Vigouroux S., Jubert C., Ceballos, P., Marie-Cardine, A., Galambrun C., Cholle C., Urmes, I.C., Petitpain N., De Carvalho Bittencourt, M., Decot V., Reppel, L., Salmon, A., Clement, L., and Bensoussan, D. (2017) Journal of Hematology & Oncology 10:102

Adoptive T-cell therapy with hexon-specific T helper-1 cells as a treatment for refractory adenovirus infection after allogeneic stem cell transplantation.

Feucht, J., Opherk, K., Lang, P., Kayser, S., Hartl, L., Bethge, W., Matthes-Martin, S., Bader, P., Albert, M. H., Maecker-Kohlhoff, B., Greil, J., Einsele, H., Schlegel, P. G., Schuster, F., Kremens, B., Rossig, C., Gruhn, B., Handgretinger, R., and Feuchtinger, T. (2015) Blood.;125:1986-94.

Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation.

Feuchtinger, T., Matthes-Martin, S., Richard, C., Lion, T., Fuhrer, M., Hamprecht, K., Handgretinger, R., Peters, C., Schuster, F., Beck, R., Schumm, M., Lotfi, R., Jahn, G., and Lang, P. (2006) Br. J. Haematol., 134:64-76.

Interferon-c capture T cell therapy for persistent Adenoviraemia following allogeneic haematopoietic stem cell transplantation.

Qasim W, Gilmour K, Zhan H, Derniame S, McNicol AM, Ip W, Hiwarkar P, Veys P, Gaspar HB. (2013) Br J Haematol. May;161(3):449-52.

BKV

BKV-specific T-cells in the treatment of severe refractory haemorrhagic cystitis after HLA-haploidentical haematopoietic cell transplantation.

Pello, O.M., Innes, A., Bradshaw, A., Finn, S.-A., Uddin, S., Bray, E., Olavarria, E., Apperley, J.F. and Pavlu, J. (2017) EurJHeam, doi: 10.1111/ejh.12848

Pre-Clinical Data

Multivirus-specific T cells

Effect of T cell subset dose on outcome of T cell-depleted bone marrow transplantation.

Kawanishi, Y., Passweg, J., Drobyski, W.-R., Rowlings, P., Cook-Craig, A., Casper, J., Pietryga, D., Garbrecht, F., Camitta, B., Horowitz, M., Juckett, M., Margolis, D., Flomenberg, N., and Keever-Taylor, C.A. (1997) Bone Marrow Transplant., 19:1069-77.

Singlevirus-specific T cells

CMV

Automated isolation of primary antigen-specific T cells from donor lymphocyte concentrates: results of a feasibility exercise.

Bunos, M., Hümmer, C., Wingenfeld, E., Sorg, N., Pfirrmann, V., Bader, P., Seifried, E., and Bönig, H. (2015) Vox Sang., 109:387-93.

Robust Production of Cytomegalovirus pp65-Specific T cells Using a Fully Automated IFN- γ Cytokine Capture System

Kim N., Nam Y-S, Keon-Il Im, Lim J-Y, Jeon Y.-W., Song Y., Lee J. W., Cho S. G. (2017) *Transfus Med Hemother* 2017;44:1-10

Automated cell enrichment of cytomegalovirus-specific T cells for clinical applications using the cytokine-capture system.

Pappanaicken, K., Figliola, M., Moyes, J. S., Huls, M.H., Tewari, P., Shpall, E. J., Champlin, R. E., and Cooper, L.J.N. (2015) *J. Vis. Exp.*; doi: 10.3791/52808; 1-10

Comparative Analysis of Clinical-scale IFN- γ -Positive T-Cell enrichment Using Partially and Fully Integrated Platforms.

Priesner, C., Esser, R., Tischer, S., Marburger M., Aleksandrova, K., Maecker-Kolhof, B., Heuft, H.-G., Goudeva, L., Blasczyk, R., Arseniev, L., Köhl, U., Eiz-Vesper, B. and Klöß, S. (2016) *Front. Immunol.* 7:393.doi: 10.3389/fimmu.2016.00393

Rapid generation of clinical-grade antiviral T cells: selection of suitable T-cell donors and GMP-compliant manufacturing of antiviral T cells

Tischer, S., Priesner, C., Heuft, H.G., Goudeva, L., Mende, W., Barthold, M., Kloeß, S., Arseniev, L., Aleksandrova, K., Maecker-Kolhoff, B., Blasczyk, R., Koehl, U., and Eiz-Vesper, B. (2014) *J. Translat. Med.*;12:336.

HLA type-independent generation of antigen-specific T cells for adoptive immunotherapy.

Hammer, M.H., Meyer, S., Brestrich, G., Moosmann, A., Kern, F., Tesfa, L., Babel, N., Mittenzweig, A., Rooney, C. M., Hammerschmidt, W., Volk, H. D., and Reinke, P. (2005) *Eur. J. Immunol.*, 35:2250-8.

Rapid generation of combined CMV-specific CD4+ and CD8+ T-cell lines for adoptive transfer into recipients of allogeneic stem cell transplants.

Rausser, G., Einsele, H., Sinzger, C., Wernet, D., Kuntz, G., Assenmacher, M., Campbell, J. D., and Topp, M. S. (2004) *Blood*, 103:3565-72.

Rapid detection, enrichment and propagation of specific T cell subsets based on cytokine secretion.

Campbell, J. D. M., Foerster, A., Lasmanowicz, V., Niemöller, M., Scheffold, A., Fahrendorff, M. Rausser, G., Assenmacher, M. and A. Richter (2010) *Clinical and Experimental Immunology*, 163: 1-10

EBV

Generation of EBV-specific T cells for adoptive immunotherapy: A novel protocol using formalin-fixed stimulator cells to increase biosafety.

Hammer, M. H, Brestrich, G., Mittenzweig, A., Roemhild, A., Zwinger, S., Subklewe, M., Beier, C., Kurtz, A., Babel, N., Volk, H. D., and Reinke, P. (2007) *J. Immunother.*,30:817-24.

AdV

Rapid Generation of full clinical-grade human antiadenovirus cytotoxic T cells for adoptive immunotherapy.

Aïssi-Rothé, L., Decot, V., Venard, V., Jeulin, H., Salmon, A., Clement, L., Mathieu, C., Rausser, G., de Carvalho, M., Stoltz, J. F., Bordigoni, P., and Bensoussan, D. (2010) *J. Immunother.*,33:414-24.

Clinical grade generation of hexon-specific T cells for adoptive T-cell transfer as a treatment of adenovirus infection after allogeneic stem cell transplantation.

Feuchtinger, T., Richard, C., Joachim, S., Scheible, M. H., Schumann, M., Hamprecht, K., Martin, D., Jahn, G., Handgretinger, R., and Lang, P. (2008) *J. Immunother.*,31:199-206.

Capture and generation of adenovirus specific T cells for adoptive immunotherapy.

Chatziandreou, I., Gilmour, K. C., McNicol, A. M., Costabile, M., Sinclair, J., Cubitt, D., Campbell, J. D., Kinnon, C., Qasim, W., and Bobby Gaspar, H. (2007) *Br. J. Haematol.*, 136:117-26.

Adenovirus-specific T-cell Subsets in Human Peripheral Blood and After IFN- γ Immunomagnetic Selection.

Qian, C., Wang, Y., Cai, H., Laroye, C., De Carvalho Bittencourt, M., Clement, L., Stoltz, J.-F., Decot, V., Reppel, L., Bensoussan D. (2016) *J Immunother*;39:27-35

Fungus-specific T cells

Clinical-scale generation of human anti-Aspergillus T cells for adoptive immunotherapy.

Tramsen, L., Koehl, U., Tonn, T., Latgé, J. P., Schuster, F. R., Borkhardt, A., Uharek, L., Quaritsch, R., Beck, O., Seifried, E., Klingebiel, T., and Lehrnbecher, T. (2009) Bone Marrow Transplant., 43:13-9.

Generation and characterization of anti-Candida T cells as potential immunotherapy in patients with candida infection after allogeneic hematopoietic stem-cell transplant.

Tramsen, L., Beck, O., Schuster, F. R., Hunfeld, K. P., Latgé, J. P., Sarfati, J., Röger, F., Klingebiel, T., Koehl, U., and Lehrnbecher, T. (2007) J. Infect. Dis., 196:485-92.

Generation of highly purified and functionally active human Th1 cells against Aspergillus fumigatus.

Beck, O., Topp, M. S., Koehl, U., Roilides, E., Simitopoulou, M., Hanisch, M., Sarfati, J., Latgé, J. P., Klingebiel, T., Einsele, H., and Lehrnbecher, T. (2006) Blood, 107:2562-9.

Tumor-specific T cells

Rapid generation of NY-ESO-1-specific CD4+ Thelper-1 cells for adoptive T-cell therapy

Kayser, S., Boß, C., Feucht, J., Witte, K. E., Scheu, A., Bülow, H. J., Joachim, S., Stevanović, S., Schumm, M., Rittig, S. M., Lang, P., Röcken, M., Handgretinger, R., and Feuchtinger, T (2015) Oncoimmunol.;4(5):DOI:10.1080/2162402X.2014.1002723

Early detection and rapid isolation of leukemia-reactive donor T cells for adoptive transfer using the IFN-g secretion assay.

Jedema, I., Meij, P., Steeneveld, E., Hoogendoorn, M., Nijmeijer, B. A., Willemze, R., and Falkenburg, J.H.(2007) Clin. Cancer Res., 13:636-43.

Review

Viral-specific T-cell transfer from HSCT donor for the treatment of viral infections or disease after HSCT.

Qian, C., Wang, Y., Reppel, L., Dáveni, M., Campidelli, A., Decot, V., Bensoussan, D. (2018) Bone Marrow Transplantation 53, 114-122

T cells for viral infections after allogeneic hematopoietic stem cell transplant.

Bollard, C.M. and Heslop, H. E. (2016) Blood 127(26):3331-3340

Recent Developments in Cellular immunotherapy for HSCT-Associated Complications.

Reis, M., Ogonek, J., Qesari, M., Borges, N. M., Nicholson, L., Preußner, L., Dickinson, A. M., Wang, X. N., Weissinger, E. M., Richter A. (2016) Front. Immunol. 7:500.

Improving T-cell therapy for Epstein-Barr Virus lymphoproliferative disorders.

Bollard, C.M. (2012) J. Clin. Oncol., 31:5-7

Rapid detection, enrichment and propagation of specific T cell subsets based on cytokine secretion.

Campbell, J. D., Foerster, A., Lasmanowicz, V., Niemöller, M., Scheffold, A., Fahrendorff, M., Rauser, G., Assenmacher, M., and Richter, A. (2011) Clin Exp Immunol., 163:1-10

Pathogen specific T-lymphocytes for the reconstitution of the immunocompromised host.

Li Pira, G., Kapp, M., Manca, F., and Einsele, H. (2009) Curr. Opin. Immunol., 21:549-56.

Adoptive T cell immunotherapy for cytomegalovirus.

Peggs, K. S. (2009) Expert. Opin. Biol. Ther., 9:725-36.



Miltenyi Biotec

Miltenyi Biotec provides products and services worldwide. Visit www.miltenyibiotec.com/local to find your nearest Miltenyi Biotec contact.

The CliniMACS® System components, including Reagents, Tubing Sets, Instruments, and PBS/EDTA Buffer, are designed, manufactured and tested under a quality system certified to ISO 13485.

In the EU, the CliniMACS System components are available as CE-marked medical devices for their respective intended use, unless otherwise stated. The CliniMACS Reagents and Biotin Conjugates are intended for in vitro use only and are not designated for therapeutic use or direct infusion into patients. The CliniMACS Reagents in combination with the CliniMACS System are intended to separate human cells. Miltenyi Biotec as the manufacturer of the CliniMACS System does not give any recommendations regarding the use of separated cells for therapeutic purposes and does not make any claims regarding a clinical benefit. For the manufacturing and use of target cells in humans the national legislation and regulations - e.g. for the EU the Directive 2004/23/EC ("human tissues and cells"), or the Directive 2002/98/EC ("human blood and blood components") - must be followed. Thus, any clinical application of the target cells is exclusively within the responsibility of the user of a CliniMACS System.

In the US, the CliniMACS CD34 Reagent System, including the CliniMACS Plus Instrument, CliniMACS CD34 Reagent, CliniMACS Tubing Sets TS and LS, and the CliniMACS PBS/EDTA Buffer, is FDA approved; all other products of the CliniMACS Product Line are available for use only under an approved Investigational New Drug (IND) application or Investigational Device Exemption (IDE). CliniMACS MicroBeads are for research use only and not for human therapeutic or diagnostic use. CliniMACS, CliniMACS Prodigy, MACS, and the MACS logo are registered trademarks or trademarks of Miltenyi Biotec GmbH and/or its affiliates in countries worldwide. Copyright ©2017 Miltenyi Biotec GmbH and/or its affiliates. All rights reserved.